Background and Objective: This study aims to evaluate the safety and efficacy of edaravone, a novel free radical scavenger, in a group of Indian patients of acute ischemic stroke. Methods: Twenty two patients of acute ischemic stroke were given 30 mg of Edaravone twice daily for 14 days by infusion. The outcome assessment was by the Modified Rankin Scale (MRS) and Barthel Index (BI). MRS score ≤ 2 at 90 days was considered as a favorable outcome. Results: Fifteen patients (68%) had favorable outcome. The mean MRS score decreased from 4.01±0.92 at baseline to 1.86±1.07 at day 90 (p<0.005). The mean Barthel index increased from 40.00±30.11 at baseline to 75.62±22.86 at day 90 (p<0.005). The changes in the MRS and BI were observed from 7 days. None of the patients experienced any adverse effect. Conclusion: Edaravone treatment was safe and effective in providing early and sustained neurological improvement in patients with acute ischemic stroke.

Cerebral Palsy is a common and devastating neurological disorder, with no medical treatment apart from physiotherapy regimes to alleviate the functional disability. Regenerative medicine using stem cells has gained momentum in recent years as a possible strategy to repair the injured brain. Present study was undertaken in a open label series to evaluate the safety, feasibility and observe for any benefi cial effects of intra-arterial infusion of autologous bone marrow derived mononuclear cells in patients with cerebral palsy with moderate disability. Functional improvement was assessed using the motor power and spasticity scales, dystonia and abnormal movements scale and the activities of daily living scales by modifi ed Barthel Index and modifi ed Rankin Scores. Serial structural imaging with MRI and functional imaging with FDG-PET scans were done. Of the 30 patients injected with an average of 10-30 million cells into each carotid artery, improvements were observed in all clinical scales, and predominantly in the disability scores. No adverse events were noted on a 12 months follow up.